ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Therapy, complementary"

  • Abstract Number: 1896 • ACR Convergence 2023

    Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale

    Pamela Gonzalez Manrique1, Vinit Gilvaz2, Ravinder Kaler3, Neha Batra3 and Anthony Reginato2, 1Roger Williams Medical Center, North Providence, RI, 2The Warren Alpert Medical School of Brown University, Providence, RI, 3Roger Williams Medical Center, Providence, RI

    Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by inflammatory polyarthritis with infrequent extra-articular involvement. The management of RA typically requires frequent clinic…
  • Abstract Number: 1914 • ACR Convergence 2023

    Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes

    Cristina Corrales Selaya1, David Martínez-Lopez2, Diana Prieto-Peña1, Fabricio Benavides1, Jose Luis Martin-Varillas3 and Ricardo Blanco4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3Hospital de Laredo, Laredo, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised mainly by the presence of inflammation and muscle weakness. The main subtypes of…
  • Abstract Number: 2015 • ACR Convergence 2023

    Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases

    Emmanuel Massy1, Etienne Mabrut1, Sabine Mainbourg2 and Cyrille Confavreux1, 1Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, 2Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69495 Pierre-Bénite, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1; CNRS, UMR 5558, 69622 Villeurbanne, Lyon, France

    Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…
  • Abstract Number: 1227 • ACR Convergence 2022

    Impact of Pain Sensitivity and Expectations on Predicting Response to Acupuncture in Fibromyalgia

    Anne Murphy1, Henry Buchtel1, Erin Zhan1, Steven E Harte1, Ishtiaq Mawla1, Eric Ichesco1, Tony Larkin1, Vitaly Napadow2 and Richard E Harris1, 1University of Michigan, Ann Arbor, MI, 2Harvard Medical School, Boston, MA

    Background/Purpose: Fibromyalgia (FM) is a common chronic pain condition for which acupuncture treatment is increasingly utilized. However, there is no universally accepted measure to predict…
  • Abstract Number: 1294 • ACR Convergence 2022

    Translation and Cross-cultural Adaptation of the CORS into Spanish

    Victoria Navarro-Compán1, Diego Benavent2, Andrea Jochems3, Dora Pascual-Salcedo3, Gijs Jochems4, Sofia Ramiro5, Wim van Lankveld6 and Chamaida Plasencia-Rodriguez7, 1Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 2La Paz University Hospital, Madrid, Spain, 3Immuno-Rheumatology Group, Hospital Universitario La Paz, Madrid, Spain, 4Promega Biotech Ibérica, Madrid, Spain, 5Leiden University Medical Center, Leiden, Netherlands, 6NA, Amsterdam, Netherlands, 7Rheumatology Department, La Paz University Hospital, Madrid, Spain

    Background/Purpose: Rheumatic diseases substantially affect the lives of patients, with complex associations between disease severity and self-perceived health status. In this regard, the Coping with…
  • Abstract Number: 1833 • ACR Convergence 2022

    Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial

    Hildrun Haibel1, Joachim Sieper1, Denis Poddubnyy2, valeria Rios-Rodriguez3, Fabian Proft2, Mikhail Protopopov4, Judith Rademacher4, Sabrina Igel5, Peter Martus6 and Christoph Stein5, 1Charité - Universitätsmedizin, Berlin, Berlin, Germany, 2Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Berlin, Germany, 5Charité University Medicine Berlin, Berlin, Germany, 6University Hospital Tübingen, Tübingen, Germany

    Background/Purpose: The current standard of intraarticular therapy in patients with inflammatory arthritis (e.g. rheumatoid arthritis; RA) or inflammatory exacerbations of osteoarthritis (OA) is the injection…
  • Abstract Number: 1876 • ACR Convergence 2022

    Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)

    Ana Campar1, Ana Sá2, Bárbara Oliveira2 and António Marinho1, 1CENTRO HOSPITALAR UNIVERSITÁRIO DO PORTO, PORTO, Portugal, 2Centro Hospitalar Universitário do Porto, Porto, Portugal

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of systemic autoimmune disorders, comprising dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), polymyositis (PM), inclusion…
  • Abstract Number: 2040 • ACR Convergence 2022

    Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, R. Hal Scofield2, Kiely Grundahl1, Lida Radfar2, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
  • Abstract Number: 0038 • ACR Convergence 2022

    STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)

    Sachin Gaurav1, Bin Lin2, Sophia Park3, Shankar Venkatraman4, David Winkler4 and Raphaela Goldbach-Mansky5, 1Translational Autoinflammatory Diseases Section, LCIM, NIAID,, Bethesda, MD, 2NIH, Bethesda, MD, 3NIAID, Bethesda, MD, 4IFM Therapeutics, Boston, MA, 5NIH/NIAID, Potomac, MD

    Background/Purpose: SAVI is a rare, autoinflammatory type I interferonopathy caused by gain-of-function mutations that cause STING activation and excessive production of type I interferons and…
  • Abstract Number: 0206 • ACR Convergence 2022

    Differences in Medicinal Cannabis Use According to Demography, Rationale, and Patient-Physician Interactions Between the United States and Canada

    kevin boehnke1, Ying He1, Tristin Smith1, marc martel2, david williams1 and Mary-Ann Fitzcharles3, 1University of Michigan, Ann Arbor, MI, 2McGill University, Montréal-Ouest, Canada, 3McGill University, Montréal, QC, Canada

    Background/Purpose: Medical cannabis (MC) is increasingly used by persons with rheumatic conditions worldwide, although legal status varies by country. In Canada, MC has been federally…
  • Abstract Number: 0288 • ACR Convergence 2022

    Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study

    Loïc Meudec1, Pauline Richebé1, Juliette Pascaud2, Xavier Mariette3 and Gaetane Nocturne4, 1Université Paris-Saclay, AP-HP-Hôpital Bicêtre, Le Kremlin Bicêtre, France, 2Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, 3Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 4APHP, Le Kremlin Bicêtre, France

    Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…
  • Abstract Number: 0551 • ACR Convergence 2022

    Medical Cannabis Use by Rheumatology Patients According to Inflammatory versus Non-Inflammatory Condition

    kevin boehnke1, Tristin Smith1, Ying He1, marc martel2, david williams1 and Mary-Ann Fitzcharles3, 1University of Michigan, Ann Arbor, MI, 2McGill University, Montréal-Ouest, Canada, 3McGill University, Montréal, QC, Canada

    Background/Purpose: Persistent pain and poor sleep are common symptoms experienced by patients with rheumatic diseases. Medical cannabis (MC) may offer symptomatic relief and is increasingly…
  • Abstract Number: 0912 • ACR Convergence 2022

    Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis

    Kristin Wipfler1, Joanna Zeiger2, Teresa Simon3, Stuart Kassan4 and Kaleb Michaud5, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2Canna Research Foundation, Boulder, CO, 3Physicians Research Center Consultant to ForWard, Toms River, NJ, 4Colorado Arthritis Associates, Lakewood, CO, 5University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Fatty acid amide hydrolase (FAAH) is a serine hydrolase that breaks down the endocannabinoid/cannabinoid receptor agonist anandamide. Variants in the FAAH gene have been…
  • Abstract Number: 0922 • ACR Convergence 2022

    Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib

    Nuria Barbarroja1, Carlos Pérez-Sánchez1, Laura Cuesta-Lopez1, Miriam Ruiz-Ponce1, Ivan Arias-de la Rosa1, Antonio Gonzalez2, Eva Perez Pampin3, Chamaida Plasencia-Rodriguez4, Ana Martinez-Feito4, Rafaela Ortega-Castro1, Jerusalem Calvo-Gutierrez5, Alejandro Balsa6, Alejandro Escudero-Contreras1, Eduardo Collantes1 and Chary López-Pedrera7, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, 3Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, 4Rheumatology Department, La Paz University Hospital, Madrid, Spain, 5IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 6Hospital La Paz Institute for Health Research, Madrid, Spain, 7Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of suffering cardiovascular disease. The analysis of the cardiovascular and cardiometabolic proteome in RA patients…
  • Abstract Number: 0930 • ACR Convergence 2022

    Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation

    Alberto Sulli, Tamara Vojinovic, Lercara Adriano, Emanuele Gotelli, sabrina Paolino, Alessandri Elisa and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy

    Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology